Lower-dose vs high-dose oral estradiol therapy of hormone receptor–positive, aromatase inhibitor–resistant advanced breast cancer: A phase 2 randomized study
Context Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to
paradoxically sensitize hormone-receptor–positive breast cancer tumor cells to low-dose
estradiol therapy. Objective To determine whether 6 mg of estradiol (daily) is a viable
therapy for postmenopausal women with advanced aromatase inhibitor–resistant hormone
receptor–positive breast cancer. Design, Setting, and Patients A phase 2 randomized trial of
6 mg vs 30 mg of oral estradiol used daily (April 2004-February 2008 [enrollment closed]) …
paradoxically sensitize hormone-receptor–positive breast cancer tumor cells to low-dose
estradiol therapy. Objective To determine whether 6 mg of estradiol (daily) is a viable
therapy for postmenopausal women with advanced aromatase inhibitor–resistant hormone
receptor–positive breast cancer. Design, Setting, and Patients A phase 2 randomized trial of
6 mg vs 30 mg of oral estradiol used daily (April 2004-February 2008 [enrollment closed]) …
